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ABSTRACT
Introduction A model of general practitioner (GP) and 
pharmacist collaboration in primary care may be an 
effective strategy to reduce medication-related problems 
and provide better support to patients after discharge. 
The aim of this study is to investigate whether a model 
of structured pharmacist and GP care reduces hospital 
readmissions in high-risk patients.
Methods and analysis This protocol details a 
stepped-wedge, cluster-randomised trial that will 
recruit participants over 9 months with a 12-month 
follow-up. There will be 14 clusters each representing 
a different general practice medical centre. A total of 
2240 participants will be recruited from hospital who 
attend an enrolled medical centre, take five or more 
long-term medicines or whose reason for admission was 
related to heart failure or chronic obstructive pulmonary 
disease. The intervention is a multifaceted service, 
involving a pharmacist integrated into a medical centre 
to assist patients after hospitalisation. Participants will 
meet with the practice pharmacist and their GP after 
discharge to review and reconcile their medicines and 
discuss changes made in hospital. The pharmacist 
will follow-up with the participant and liaise with other 
health professionals involved in the participant’s care. 
The control will be usual care, which usually involves a 
patient self-organising a visit to their GP after hospital 
discharge. The primary outcome is the rate of unplanned, 
all-cause hospital readmissions over 12 months, which 
will be analysed using a mixed effects Poisson regression 
model with a random effect for cluster and a fixed effect 
to account for any temporal trend. A cost analysis will be 
undertaken to compare the healthcare costs associated 
with the intervention to those of usual care.
Ethics and dissemination The study has received ethical 
approval (HREC/16/QRBW/410). The study findings will 
be disseminated through peer-reviewed publications, 
conferences and reports to key stakeholders.
Trial registration number ACTRN12616001627448
INTRODUCTION
The transition of patients with chronic and 
complex conditions from hospital to the 
community setting is a critical time that 
is associated with medication misadven-
ture and re-hospitalisation.1 Up to 50% of 
patients discharged from medical wards have 
an unplanned readmission within 1 year.2–4 
Rates are higher in the elderly and those on 
multiple medications.5–7
Medication-related problems are one of 
the most common reasons for readmissions 
to hospital and include adverse drug events, 
suboptimal therapy and poor medication 
adherence.4 8 Patients often leave hospital with 
complex care plans and substantial changes 
to their medication regimens.9 In Australia, 
these changes are usually communicated to the 
patient’s general practitioner (GP), commu-
nity pharmacy and other health professionals 
involved in the patient’s care via a discharge 
summary. Discharge summaries can take time 
to reach primary care providers and often lack 
key information, such as medication changes, 
pathology tests that were performed or are 
pending and agreed treatment plans.10 This 
Strengths and limitations of this study
 ► A model of GP and pharmacist collaboration 
provides an opportunity to improve health outcomes 
in patients discharged from hospital.
 ► The stepped-wedge study design is robust and 
pragmatic, enabling the intervention to be offered 
to every medical centre involved by the end of the 
study period.
 ► Multi-skilled research team involving clinicians, 
health services researchers, a biostatistician and 
health economists.
 ► Strong stakeholder participation contributing to the 
protocol design.
 ► Blinding of the intervention is not possible to 
participants and staff at the medical centre.
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can lead to medication discrepancies, such as continuing 
discontinued medication, omitting prescribed medication 
and not implementing dose changes.11 Patients who have a 
medication discrepancy are twice as likely to be readmitted 
to hospital within 30 days.12
There have been a number of interventions targeted 
towards optimising medicine use and improving the 
timeliness of information leaving hospitals to minimise 
medication discrepancies and reduce hospital read-
missions.13–16 A common intervention used to reduce 
hospital readmissions is medication reconciliation. The 
literature exploring the efficacy of medication recon-
ciliation at hospital discharge to reduce readmissions is 
mixed. A recent meta-analysis investigated the effect of 
pharmacist-led medication reconciliation at hospital tran-
sition.16 Most of the included studies matched a patient’s 
preadmission medication to their discharge medica-
tion and reconciled any differences. The meta-analysis 
showed there was a 19% reduction in readmissions for 
those receiving pharmacist-led medication reconciliation 
compared with usual care.16 Other outcomes included a 
reduction in emergency department (ED) visits (28%) 
and adverse drug event-related readmissions (67%). 
These reductions would be anticipated to be associated 
with substantial cost savings. The findings differ to an 
earlier systematic review that reported hospital staff-led 
medication reconciliation had minimal effect on read-
missions.17 However, many of the studies included in the 
earlier systematic review did not recruit high-risk patients, 
which may be one reason why certain interventions are 
not successful. Previous hospitalisations or ED visits, 
taking multiple long-term medicines and being admitted 
for heart failure or chronic obstructive pulmonary disease 
(COPD) are common risk factors for readmission.3 6 7 18 
Interventions targeting participants with these risk factors 
appear more effective at reducing readmissions.17 19
Another approach to reducing readmissions has 
been to conduct a medication review immediately after 
discharge.20–22 Pharmacists working within a primary care 
clinic undertaking medication review, with a focus on 
medication reconciliation and patient education, showed 
a reduction in hospital readmissions in two studies.20 21 
Tedesco et al22 were limited by the study design and small 
sample size, although they observed a trend (p=0.27) 
towards decreased readmissions in the intervention group 
compared with control. The authors noted that there were 
fewer readmissions in those who interacted with the phar-
macist face to face versus by telephone (p=0.05).
Overall, common characteristics among effective 
interventions include allowing for direct communi-
cation between the pharmacist and the prescriber,23 
involving postdischarge care20 and targeting high-risk 
patients.17 19 24 A model of GP and pharmacist collabora-
tion assisting patients during transitions of care may be 
a clinically relevant and cost-effective strategy to reduce 
unplanned readmissions.
A practice pharmacist is ‘a pharmacist who delivers 
professional services from or within a general practice 
medical centre with a coordinated, collaborative and inte-
grated approach with an overall goal to improve the quality 
use of medicines of the practice population’.25 Despite 
widespread support, the Australian setting is in its infancy 
in exploring this model of practice that is restricted by 
the absence of a dedicated and sustainable remunera-
tion model.26 The vast majority of Australian pharmacists 
working in primary care do so in a community pharmacy 
with one study reporting only 26 pharmacists working 
within or from a general practice in 2013.25 Although 
performing comprehensive medication reviews is a core 
activity of practice pharmacists, they are also involved 
in a range of clinician-level and practice-level activities. 
These include providing drug information and educa-
tion as well as clinical prescribing review with prescriber 
feedback.26 Being co-located within the patient’s medical 
home allows for greater communication and collabo-
ration with primary healthcare providers and access to 
patient’s medical records.27 28 This allows quick identifica-
tion and resolution of medication-related problems with 
the prescribing GP, linking with community pharmacies 
to enhance continuity of care and liaising with hospitals 
when patients are discharged. Practice pharmacists inte-
grated into the general practice medical team have shown 
favourable outcomes, with improvements in clinical 
outcomes, identification and reduction in medication-re-
lated problems and improved medication adherence.27 A 
study in the Netherlands is currently exploring whether 
integrating non-dispensing pharmacists into the primary 
care team can reduce medication-related hospital admis-
sions in patients considered at risk of adverse drug 
events.29
A model of GP and pharmacist collaboration provides 
an opportunity to improve information transfer between 
hospitals and primary care, reduce medication-related 
problems and discrepancies, and provide better support to 
patients after discharge to reduce unplanned hospital read-
missions.
The aim of this study is to investigate whether a model 
of structured pharmacist and GP care reduces unplanned 
hospital readmissions in high-risk patients.
The primary objective is to investigate whether inte-
grating a pharmacist into the general practice team will 
reduce unplanned hospital readmissions at 12 months.
Secondary objectives are to:
1. Investigate whether integrating a pharmacist into 
the general practice team will:
a. reduce unplanned hospital readmissions at 30 
days, 3 and 6 months;
b. reduce ED presentations at 30 days, 3, 6 and 12 
months;
c. improve the timeliness of receiving the hospital 
discharge treatment plan in primary care;
d. increase the number of participants visiting 
their GP within 1 week of discharge.
2. assess the cost savings associated with a model of 
GP–pharmacist collaboration of care in reducing 
hospital readmissions;
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3. describe the activities performed by practice 
pharmacists and GPs when transitioning a patient 
from hospital to primary care;
4. explore the views and experiences of the 
intervention from the perspective of the GP, 
practice pharmacists, community pharmacists and 
participants involved in the study.
METHODS AND ANALYSIS
This protocol was developed in accordance with the Stan-
dard Protocol Items: Recommendations for Interventional 
Trials (SPIRIT) 2013 Statement30 (see online supplemen-
tary SPIRIT 2013 checklist). Reference was also made to 
CONSORT statement extension for cluster randomised 
trials31 and the recommended modifications for stepped-
wedge designs.32
Study design and setting
This is a stepped-wedge, cluster-randomised trial that 
will recruit participants over 9 months with a 12-month 
follow-up period. Participants will be recruited during 
their hospital admission from public and private hospitals 
across South East Queensland, Australia. The interven-
tion will be located in 14 different medical centres. Cluster 
randomisation will be used to allow for randomisation to 
occur at the level of the cluster (medical centre) instead 
of the participant.
A stepped-wedge trial has a unidirectional cross-over 
design where all clusters (medical centres) begin in 
the control phase and cross over to the intervention 
at different time points. The design involves an initial 
period where no medical centres are exposed to the 
intervention (control phase). Then, at regular intervals, 
two medical centres will be randomised to cross over from 
control to the intervention. After 8 months, all medical 
centres will be exposed to the intervention. The length 
of time a medical centre receives the intervention may 
vary between 1 and 7 months (figure 1). A 1-month tran-
sition phase is included where the medical centre is not 
considered as being in control or intervention and does 
not contribute to analysis. This transition period allows 
for the time it takes to embed the intervention into a 
medical centre.32
This design was employed to: increase medical centre 
participation rates by offering the intervention to all 14 
medical centres by the end of the study period; measure 
and adjust for possible underlying temporal trends (such 
as seasonal variation in admissions) and prevent poten-
tial direct/indirect educational effects of the intervention 
carrying over to the control phase (which precludes a 
traditional cross-over design).
Study population
Patients in hospital who are considered at risk of read-
mission and attending an enrolled medical centre will be 
invited to participate in the study.
Eligibility criteria
Inclusion criteria
1. have nominated a GP working in an enrolled 
medical centre in their hospital records;
2. prescribed ≥5 long-term medicines on discharge 
OR primary discharge diagnosis of congestive heart 
failure OR exacerbation (either infective or non-
infective) of COPD;
3. ≥18 years of age.
Exclusion criteria
1. receiving active radiation therapy or chemotherapy 
for malignant conditions;
2. admission was for planned dialysis;
3. in palliative care as reflected by the treatment 
regimen (eg, cessation of preventative medicines);
4. unable to attend a medication review and the 
follow-up within the time frame.
Recruitment
Participants
Patients in public and private hospitals located across the 
study geographical region who have met the eligibility 
criteria will be invited to participate in the study. Research 
Figure 1 Schematic representation of the stepped-wedge study design.
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assistants will screen patients daily for eligibility and 
recruit those who give consent. Participants will comprise 
a convenience sample, as they will only be recruited when 
the research assistant is present.
Medical centres
To ensure we capture the required sample size, medical 
centres that are in a region that have a higher than average 
number of hospitalisations will be approached. To ensure 
the results are translatable, two of the 14 medical centres 
will be aboriginal community controlled health organisa-
tions that focus on improving the health of indigenous 
Australians. For logistical reasons, the aboriginal commu-
nity controlled health organisations will be composed of 
groups of two to three small medical centres (treated as 
one single cluster for the purposes of randomisation).
Inclusion criteria
1. space to accommodate a co-located pharmacist in 
a private room;
2. anticipate capturing the required sample size (20 
participants per month).
Exclusion criteria
1. Currently have a practice pharmacist integrated 
into the medical centre.
Practice pharmacists
Practice pharmacists will be recruited through an expres-
sion of interest advertisement distributed through 
national pharmacy associations. It will be essential that 
the pharmacist is registered to practice in Australia, has 
recent experience conducting medication reviews and 
working in a multidisciplinary team. All pharmacists 
will have professional registration and indemnity insur-
ance. A particular pharmacist may work across multiple 
medical centres during the intervention. Medical centres 
randomised to have a short intervention phase may have 
a pharmacist that has had experience in a medical centre 
that has been randomised to have a longer intervention 
phase.
Study procedure
Following assessment of eligibility and participant 
consent, depending on which phase the cluster is in and 
time of recruitment, the participant will be allocated to 
the control or intervention. Figure 2 provides an overview 
of the study procedure.
Control phase
If the participant’s medical centre is in the control phase, 
they will receive usual care. In Australia, usual care would 
mean the patient would consult their GP as per normal 
standards for that practice for a patient discharged from 
hospital. There will be no pharmacist in the medical 
centre during the control phase. Medication liaison 
in the form of a discharge medication record may be 
provided to patients on discharge from hospital and may 
be included in the hospital discharge summary to the GP.
Lead in phase
This phase will be used to assist the pharmacist integrating 
into the medical centre, prior to the intervention begin-
ning. For greatest success, it will be imperative that the 
pharmacist establishes relationships with the GPs within 
the medical centre. To facilitate this, the practice phar-
macist will be encouraged to meet with each GP, attend 
meetings and give a presentation to the medical staff on 
the role of the pharmacist in the study. The pharmacist 
may also visit the local community pharmacies to intro-
duce themselves, explain the study and that they may be 
contacted by the practice pharmacist for referrals (home 
medicine reviews) and additional monitoring (blood 
pressure and others).
Intervention phase
If the participant’s medical centre is in the intervention 
phase, the participant will receive the intervention.
The intervention is a multifaceted and collaborative 
service, involving a practice pharmacist integrated into 
a medical centre to assist patients in transitioning back 
into primary care after hospitalisation. The intervention 
is targeted at the level of the medical centre. A practice 
pharmacist will be integrated into each medical centre 
during the intervention phase for approximately 12 hours 
per week, spread across multiple days. There will be three 
components to the intervention that will apply to each 
participant in the intervention phase.
Medication management consultation
Participants will receive a face-to-face medication 
management consultation (approximately 45–60 min) 
with the practice pharmacist in a private room at the 
attended medical centre. In circumstances where the 
participant cannot attend their medical centre, the 
participant may elect to have a home visit by the practice 
pharmacist.
The initial medication management consultation will 
occur as soon as possible after discharge, ideally within 
five business days of discharge. During this time, the 
pharmacist will perform a comprehensive medication 
review to identify any medication-related problems, assess 
medication adherence, review the participant’s medica-
tion discharge letter and discuss any changes made to 
medication during the hospital admission. The pharma-
cist will also review the participant’s medical records at 
the practice and reconcile any differences as required. 
The pharmacist will discuss the intended treatment plan 
and any problems or concerns the participant may have 
regarding their medication and/or medical conditions. 
The pharmacist may also liaise with the participant’s 
community pharmacy, hospital pharmacist and other 
prescribers to directly clarify any issues or anomalies 
with the participant’s records and to communicate the 
changes made to the participant’s medication regimen in 
hospital.
The practice pharmacist will also aim to enrol partici-
pants into a national online health record to allow better 
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Figure 2 Diagram of REMAIN HOME patient recruitment, randomisation, intervention and control arms. COPD, chronic 
obstructive pulmonary disease; GP, general practitioner; REMAIN HOME, Reducing Medical Admissions into Hospital through 
Optimising Medicines.
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transfer of information between health professionals 
involved in the participant’s care.
Consultation with GP
Directly after the consultation with the pharmacist, the 
participant will then have a consultation with their GP 
to consider any recommendations made by the phar-
macist and discuss the recent admission to hospital and 
future management plans.
Pharmacist follow-up
The pharmacist will follow-up with the participant face to 
face or via the telephone within five business days of the 
initial consultation.
The pharmacist may also liaise with the participant’s 
GP and other health professionals involved in the partici-
pant’s care. This may include a referral to the participant’s 
community pharmacy.
Additional follow-up with the participant will be deter-
mined by the pharmacist or GP based on clinical need for 
each participant.
Outcome follow-up
Participants will be followed up to 12 months from day of 
hospital discharge. This will be done through collection 
of routine data from the hospital and medical centre.
Participant withdrawal
For intention-to-treat purposes, we aim to collect routine 
data from all participants, regardless of whether they 
complete the study. If a participant decides to withdraw, 
we will request consent to collect their follow-up data.
Medical centre withdrawal
It is unlikely that medical centres will withdraw once they 
have agreed to take part. If a medical centre chooses not 
to fully engage with the intervention, the research team 
will request to collect follow-up data. This follow-up data 
collection will require minimal effort from practice staff. 
If a medical centre withdraws before commencement of 
recruitment, the next medical centre on the list will be 
contacted and invited to participate in the study.
Outcomes
The primary outcome is the rate of unplanned, all-cause 
hospital readmissions 12 months after discharge in the 
intervention group compared with control/usual care.
For the purposes of this study, an unplanned readmis-
sion is defined as any subsequent admission following the 
index hospital admission that is an emergency.
Secondary outcomes are:
1. the rate of unplanned, all-cause hospital 
readmissions at 30 days, 3 and 6 months after 
discharge in the intervention group compared with 
control/usual care;
2. the rate of ED presentations at 30 days, 3, 6 and 12 
months after discharge in the intervention group 
compared with control/usual care;
3. number of hospital treatment plans received within 
five business days and 30 days after discharge in the 
intervention group compared with control/usual 
care;
4. number of participants reviewed by their GP within 
a week of discharge in the intervention group 
compared with control/usual care;
5. number of visits to the enrolled medical centre 
within 12 months after discharge in the intervention 
group compared with control/usual care;
6. costs to the healthcare system associated with the 
intervention (including the costs of providing the 
intervention, unplanned hospital readmissions, ED 
presentations and related GP visits) at 30 days, 3, 6 
and 12 months after discharge in the intervention 
group compared with control/usual care;
7. description of views of the intervention from GPs, 
practice pharmacists, community pharmacists and 
participants involved in the study.
Sample size
Sample size was calculated for the primary outcome, the 
rate of unplanned, all-cause readmissions at 12 months 
from date of hospital discharge, using a method that 
takes into account the: intracluster correlation coefficient 
(ICC), expected baseline number of readmissions, effect 
of the intervention and power of the study. We followed 
methods described by others to determine the sample size 
needed, assuming a random effect for cluster (medical 
centre) and a fixed effect for each step to account for 
time.33 34 We have been conservative in our estimate of the 
ICC as we have limited a priori data to inform this value 
and also because the ICC is a process outcome, which 
usually have larger ICCs.35 Although the analysis will be 
a Poisson regression of rate of readmission, the study has 
been powered on a binary proportion outcome. This is 
because there is no data on which to estimate current rate 
of readmission and sample size methodology for stepped-
wedge studies does not currently exist for rate outcomes. 
This is a limitation of the sample size calculation, but the 
estimate of power will be conservative because the anal-
ysis will make full use of the number of readmissions.
Literature from Australian studies suggests that 45% 
of patients discharged from medical inpatient units 
and 61% from Geriatrics Evaluation and Management 
units have an unplanned readmission within 1 year.2 5 A 
meta-analysis of interventions performing pharmacist-led 
medication reconciliation alone at hospital transition 
found a relative risk reduction in all-cause readmissions 
of 19% by the intervention across included studies.16 
This meta-analysis only included studies conducting 
medication reconciliation, which is only one facet of the 
planned intervention. It is expected that the intervention 
in the REMAIN HOME study will be more effective than 
medication reconciliation alone. A hospital discharge 
programme involving medication reconciliation and 
telephone follow-up showed an absolute risk reduc-
tion in readmissions (combined with ED visits) of 14% 
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in the general medicine sample.36 In a pharmacist-led, 
home-based medication review after discharge, 45% of 
patients in the control group experienced a readmission 
compared with 28% in the intervention, resulting in an 
absolute risk reduction of 17%.37
This study is powered to detect a smaller effect size than 
the studies conducted by Jack et al36 and Naunton and 
Peterson37 that are described above. This is a conserva-
tive estimate and smaller effect sizes are also likely to be 
clinically important. We expect only minimal variation in 
cluster sizes and so have not allowed for varying cluster 
sizes. With 14 clusters, and 20 patients recruited per 
cluster per month (except during the transition phase), 
it gives an expected total sample size of 2240 participants. 
Using these estimates and expected loss to follow-up of 
approximately 20%, the design will have in the region 
of 80%–90% power to detect a change in proportions of 
unplanned readmissions from 0.3 to 0.2 for a range of 
ICCs (from 0.05 to 0.15).
Randomisation
The unit of randomisation is the study medical centre, not 
the participant. Once 14 medical centres have provided 
consent to be involved in the study, each enrolled medical 
centre will be randomised to a transition step by the 
study statistician (KH). This will determine how long the 
medical centre is in the control and intervention phase. 
Stratified randomisation will be used to achieve an even 
balance of medical centres across the two geographical 
regions the study is set over while maintaining rando-
misation. Each medical centre will be informed of their 
randomisation status 1 month prior to their transition 
phase to be able to make the necessary arrangements for 
the pharmacist to integrate into the medical centre at the 
required time.
Allocation concealment and blinding
Research assistants recruiting participants will remain 
blinded to the randomisation schedule and will have no 
contact with the practice pharmacists throughout the 
study to ensure allocation concealment. Once the patient 
has been enrolled, the research assistant will notify the 
project coordinator who will pass the participant’s details 
on to the practice pharmacist performing the interven-
tion. If the medical centre the participant attends is in 
the control phase, the medical centre will not be notified.
Blinding of the intervention to staff at the medical 
centre and to participants is not possible as the presence 
of the pharmacist in the medical centre will indicate they 
are in the intervention phase. The statistician performing 
the analysis will be blinded to which group is the control 
and intervention group.
Data collection
Data will be collected from the participant’s hospital and 
medical centre records by the project coordinator to 
determine whether a participant experienced a primary 
or secondary outcome.
Demographics and reason for admission at enrolment 
and subsequent admissions in the 12-month follow-up 
will be collected through participant hospital records.
Medical centre records will be used to identify whether a 
discharge treatment plan was received and the timeliness 
and number of GP visits during the 12-month follow-up 
period for each participant.
The practice pharmacist will record the details 
around each interaction with the participant in their 
practice medical notes as per normal standards. Phar-
macist will also complete forms for each participant 
in the intervention phase to record their activities 
(see online supplementary file 1) at the initial consulta-
tion and follow-up(s). These records will be based on the 
DOCUMENT system that classifies drug-related prob-
lems and recommendations into coded categories and 
subcategories.38
Feedback on the acceptability, benefits and chal-
lenges of the GP-pharmacist model of care from the 
practice pharmacists, GPs, community pharmacies 
and participants (intervention only) will be collected 
(see online supplementary file 2). The views and experi-
ences of the GPs will be measured through the validated 
questionnaire, Attitudes Toward Collaboration Instru-
ment for GPs (ATCI-GP).28 Participation in these surveys 
will be optional.
Data management and monitoring
All data collected from participants, pharmacists and 
medical centre staff will remain confidential at all times. 
Paper documents will be stored securely in a locked 
cabinet. Electronic records will be stored as a database on 
a password-protected server. This is a high-quality, secure 
server and is backed up regularly.
The quality of collected data, recruitment and reten-
tion rates will be monitored throughout the trial.
This model of care is associated with minimal risk of 
harm. At all times during the trial, the participant will be 
under the care of their GP. GPs in the enrolled medical 
centres are not part of the research team and therefore 
will be an independent reviewer to assess and report any 
adverse events that occur during the study that may be 
related to the intervention. Any adverse events that come 
to the attention of the practice pharmacist or research 
team thought to be related to the intervention will be 
forwarded to the study safety committee. A study safety 
committee will be established that will consist of clini-
cians that are independent to the research project and 
will review any adverse events reported or thought to be 
related to the intervention.
Analysis
An intention-to-treat analysis will be conducted. All 
participants will be included in the analysis. Each medical 
centre will be classified as being in the intervention or the 
control phase based on their prespecified randomised 
cross-over time, regardless of whether crossover is 
achieved at that time.32
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In the primary analysis, differences in readmissions 
will be modelled using a mixed effects Poisson regres-
sion model with an offset to incorporate the number of 
days of follow-up, a random effect for cluster and a fixed 
effect for each step to account for any temporal trend. 
Temporal trends may include seasonal variation in read-
missions or changes in practice. We also intend to allow 
for both levels of clustering at the analysis stage—clus-
tering by hospital and medical centre. This will be done 
by including both a random effect for medical centres 
and hospitals. If this model does not converge, we will 
include a fixed effect for hospital (as there will not be 
many hospitals) and a random effect for medical centre. 
In addition, a sensitivity analysis will be conducted with a 
random effect for pharmacist. This will allow for pharma-
cists working across multiple medical centres. Follow-up 
time will be the number of days from index admission 
discharge to the earliest of 12 months post discharge, 
death or loss to follow-up.
Secondary analysis will be conducted using similar tech-
niques but using different link functions as appropriate. 
Descriptive statistics will be used to report the level of 
agreement with survey statements used to elicit the views 
of the intervention from GPs, practice pharmacists and 
participants involved in the study.
We will also report estimates of intracluster correlations.
Subgroup analyses will be hypothesis generating to 
assess whether the effect of the intervention varies by:
i. age: <65 years, 65–74 years, ≥75 years;
ii. Aboriginal community controlled health 
organisations versus non-aboriginal community 
controlled health organisations;
iii. level of patient frailty (defined by the Clinical 
Frailty Scale39): nine categories from 1 (very fit) to 
9 (terminally ill);
iv. number of follow-up appointments with practice 
pharmacist;
v. time to consultation after discharge: ≤5 days versus >5 
days;
vi. Socio-Economic Indexes for Areas: quantiles from 
most disadvantaged to least disadvantaged;
vii. number and type of comorbidities at index hospital 
discharge;
viii. primary reason for indexed admission;
ix. number of prescribed medicines at index hospital 
discharge: 1–4, 5–10 and >10;
x. residing in a residential aged care facility (RACF) 
versus non-RACF.
Economic evaluation
The direct healthcare costs that are associated with the 
intervention will be measured and compared with the 
costs associated with usual care. The intervention costs 
will include pharmacist time to deliver the collabora-
tive service. The resource use for both intervention and 
control periods will also be estimated by recording the 
number, length and diagnosis-related group (DRG) allo-
cations for unplanned hospital readmissions, the number 
and triage code for ED presentations and the number of 
GP visits, over the period of study follow-up. The primary 
source of hospital cost estimates, by DRG, will be derived 
from the National Efficient Cost and National Efficient 
Price data that are collected and published annually 
by Australia’s Independent Hospital Pricing Authority 
(IHPA).40 41 This analysis will be restricted to direct 
medical and staffing costs to produce a meaningful basis 
of comparison with hospitals, primary carers, government 
agencies and private health insurers. The cost analysis will 
adjust for time preference using discounting and for clus-
tering on location.
Ethics and dissemination
Ethics approval has been obtained through the Royal 
Brisbane and Women’s Hospital Human Research Ethics 
Committee (HREC/16/QRBW/410).
The findings from this study will be disseminated 
through peer-reviewed publications, conferences and 
reports to key stakeholders. The results will help inform 
state, federal and private stakeholders operating in the 
health sector to implement evidence-based models for the 
transition of care of patients with chronic and complex 
diseases between hospital and the community settings. 
The evidence gained from this study will also inform 
the establishment of funding models to support the 
role of pharmacists in general practice medical centres 
in Australia by considering the clinical, humanistic and 
economic impacts.
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